

<b>Notice of Allowability</b>	<b>Application No.</b>	<b>Applicant(s)</b>	
	10/030,301	PEYMAN ET AL.	
	<b>Examiner</b>	<b>Art Unit</b>	
	Tamthom N. Truong	1624	

**-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address--**

All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. **THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS.** This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.

1. ☒ This communication is responsive to 11-21-03.
2. ☒ The allowed claim(s) is/are 1-8, and 11.
3. ☐ The drawings filed on \_\_\_\_\_ are accepted by the Examiner.
4. ☒ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
  - a) ☒ All    b) ☐ Some\*    c) ☐ None    of the:
    1. ☐ Certified copies of the priority documents have been received.
    2. ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
    3. ☒ Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)).
- \* Certified copies not received: \_\_\_\_\_.
5. ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application) since a specific reference was included in the first sentence of the specification or in an Application Data Sheet. 37 CFR 1.78.
  - (a) ☐ The translation of the foreign language provisional application has been received.
6. ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121 since a specific reference was included in the first sentence of the specification or in an Application Data Sheet. 37 CFR 1.78.

Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application. **THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.**

7. ☐ A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.
8. ☐ CORRECTED DRAWINGS (as "replacement sheets") must be submitted.
  - (a) ☐ including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached
    - 1) ☐ hereto or 2) ☐ to Paper No. \_\_\_\_\_.
  - (b) ☐ including changes required by the proposed drawing correction filed \_\_\_\_\_, which has been approved by the Examiner.
  - (c) ☐ including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No. \_\_\_\_\_.

Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the margin according to 37 CFR 1.121(d).

9. ☐ DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.

#### Attachment(s)

- |   |   |
|---|---|
| 1 <input checked="" type="checkbox"/> Notice of References Cited (PTO-892)                                | 5 <input type="checkbox"/> Notice of Informal Patent Application (PTO-152)          |
| 2 <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)                       | 6 <input checked="" type="checkbox"/> Interview Summary (PTO-413), Paper No. _____. |
| 3 <input type="checkbox"/> Information Disclosure Statements (PTO-1449 or PTO/SB/08),<br>Paper No. _____  | 7 <input checked="" type="checkbox"/> Examiner's Amendment/Comment                  |
| 4 <input type="checkbox"/> Examiner's Comment Regarding Requirement for Deposit<br>of Biological Material | 8 <input checked="" type="checkbox"/> Examiner's Statement of Reasons for Allowance |
|   | 9 <input type="checkbox"/> Other  |

### EXAMINER'S AMENDMENT

An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Mr. Charles A. Muserlian on 01-16-04.

The application has been amended as follows:

Claim 1: page 4, line 4, (in the definition of  $R^3$ ), delete the second "**(C<sub>2</sub>-C<sub>18</sub>)-alkenyl**", and insert **-(C<sub>2</sub>-C<sub>18</sub>)-alkynyl—** in its place;

Claim 2: page 8, line 5, (in the definition of  $R^3$ ), delete the second "**(C<sub>2</sub>-C<sub>18</sub>)-alkenyl**", and insert **-(C<sub>2</sub>-C<sub>18</sub>)-alkynyl—** in its place;

Claim 3: page 11, delete the second definition of  $R^3$  on lines 12-26. That is, delete the paragraph of " **$R^3$  is selected from the group consisting of hydrogen, fluorine, chlorine, cyano, nitro, ..., and  $R^6C(O)N(R^5)R^7$ ,**"

*Allowable Subject Matter*

Applicant's amendment of 11-21-03 has overcome the previous rejections of 112/1<sup>st</sup> and 2<sup>nd</sup> paragraphs by amending the definition of R<sup>3</sup>, deleting the term "prodrugs", deleting "3-deazapurine..., 7-deazapurine...or a 7-deaza-8-azapurine", and deleting the phrase "act as vctronectin receptor antagonist", and the phrase "inhibiting vitronectin binding". Thus, said rejections are withdrawn herein.

Claims 9 and 10 have been cancelled. With no other outstanding rejection, claims 1-8, and 11 are allowed.

The following is an examiner's statement of reasons for allowance:

The closest reference, **Gilligan et. al.** (US 6,365,589 B1), teaches compounds of imidazo-pyridine and imidazo-pyridazine. However, such a ring system is not equivalent to the purine as claimed herein. An update search yields a reference of **DeSimone et. al.** (US 2003/0216390) which provides a genus of a bicyclic system that seems to include purine. However, the teaching of DeSimone et. al. does not provide a preferred embodiment for a purine subgenus. Therefore, there is no express motivation in said teaching to select purine compounds as claimed herein. Since there is no nexus between two references, there is no motivation to combine them for a prima facie case of obviousness.

Art Unit: 1624

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

-----  
Any inquiry concerning this communication or earlier communications from the examiner should be directed to Tamthom N. Truong whose telephone number is 703-305-4485. The examiner can normally be reached on M-F (9 am - 5:30 pm) starting from January 12<sup>th</sup>, 2004.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Mukund Shah can be reached on 703-308-4716. The fax phone numbers for the organization where this application or proceeding is assigned are 703-308-4556 for regular communications and 703-308-4556 for After Final communications.


Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703-308-1235.



T. Truong

\*\*\*

January 16, 2004



Richard L. Raymond  
Acting SPE  
Art Unit 1624